What is the address of MEDOXY?

The registered office of MEDOXY is located at Rue des Bouvreuils(N) 10, 4121 Neupré.

Is MEDOXY still active?

Yes. According to the CBE (31 October 2026) MEDOXY is active, legal situation “Normale toestand”, started on 2 September 2022.

Is MEDOXY registered on Peppol?

Yes, MEDOXY is registered on the Peppol network with ID 0208:0790403510.

What is the enterprise number of MEDOXY?

The enterprise number of MEDOXY is BE0790403510.

When was MEDOXY founded?

MEDOXY was founded on 2 September 2022.

Is MEDOXY a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 September 2022; 4 annual accounts filed, latest fiscal year 2025.

How much profit did MEDOXY make in 2025?

MEDOXY posted a profit after taxes of € 12,462 in financial year 2025.

What is the revenue of MEDOXY?

As a small company, MEDOXY is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 83,242.

MEDOXY (Private Limited) - Neupré - BE0790403510

Dossier MEDOXY, printed on 1 November 2026 from databakkes.be/en/0790403510/medoxy. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

MEDOXY from Neupré, company number BE0790403510, closed financial year 2025 with a result of € 12,462 after tax. For that financial year MEDOXY recorded a gross margin of € 83,242 and equity of € 108,773. Compared with financial year 2024, the result moved from € 60,108 to € 12,462. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.

What it is worth Healthy

€ 108,773

▼ 45% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 12,462

▼ 79% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 70,501

▼ 60% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 100,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Wage cost

€ 25

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 18,318

▼ 12% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 66 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 308,408

▲ € 288,959 vs 2024

€ 4,643 is repaid this year. At this pace the long-term loan is gone in ≈ 66 years.

Owed to suppliers

€ 27

▲ 3% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 18,928

▼ 32% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 41,920 Gross margin 2022: € 41,920 First fiscal year in the series	€ 131,897 Gross margin 2023: € 131,897 ▲ 215% vs 2022 (€ 41,920) Favourable step	€ 92,379 Gross margin 2024: € 92,379 ▼ 30% vs 2023 (€ 131,897) Unfavourable step	€ 83,242 Gross margin 2025: € 83,242 ▼ 10% vs 2024 (€ 92,379) Unfavourable step	▼ 10%
Profit after taxes	€ 31,245 Profit after taxes 2022: € 31,245 First fiscal year in the series	€ 102,958 Profit after taxes 2023: € 102,958 ▲ 230% vs 2022 (€ 31,245) Favourable step	€ 60,108 Profit after taxes 2024: € 60,108 ▼ 42% vs 2023 (€ 102,958) Unfavourable step	€ 12,462 Profit after taxes 2025: € 12,462 ▼ 79% vs 2024 (€ 60,108) Unfavourable step	▼ 79%
Equity	€ 33,245 Equity 2022: € 33,245 First fiscal year in the series	€ 136,204 Equity 2023: € 136,204 ▲ € 102,958 vs 2022 (€ 33,245) Favourable step	€ 196,312 Equity 2024: € 196,312 ▲ 44% vs 2023 (€ 136,204) Favourable step	€ 108,773 Equity 2025: € 108,773 ▼ 45% vs 2024 (€ 196,312) Unfavourable step	▼ 45%
Total debts	€ 12,849 Total debts 2022: € 12,849 First fiscal year in the series	€ 30,164 Total debts 2023: € 30,164 ▲ 135% vs 2022 (€ 12,849) Unfavourable step	€ 47,488 Total debts 2024: € 47,488 ▲ 57% vs 2023 (€ 30,164) Unfavourable step	€ 357,058 Total debts 2025: € 357,058 ▲ € 309,569 vs 2024 (€ 47,488) Unfavourable step	▲ € 309,569
Cash	€ 44,292 Cash 2022: € 44,292 First fiscal year in the series	€ 118,172 Cash 2023: € 118,172 ▲ 167% vs 2022 (€ 44,292) Favourable step	€ 175,329 Cash 2024: € 175,329 ▲ 48% vs 2023 (€ 118,172) Favourable step	€ 70,501 Cash 2025: € 70,501 ▼ 60% vs 2024 (€ 175,329) Unfavourable step	▼ 60%
Land & buildings	-	-	-	€ 318,790 Land & buildings 2025: € 318,790 First fiscal year in the series
Retained profit	€ 31,245 Retained profit 2022: € 31,245 First fiscal year in the series	€ 134,204 Retained profit 2023: € 134,204 ▲ € 102,958 vs 2022 (€ 31,245) Favourable step	€ 194,312 Retained profit 2024: € 194,312 ▲ 45% vs 2023 (€ 134,204) Favourable step	€ 106,773 Retained profit 2025: € 106,773 ▼ 45% vs 2024 (€ 194,312) Unfavourable step	▼ 45%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 100,000 Dividend 2025: € 100,000 Unchanged (€ 0) Unchanged
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 19,449 Bank debt 2024: € 19,449 Unchanged (€ 0) Unfavourable step	€ 308,408 Bank debt 2025: € 308,408 ▲ € 288,959 vs 2024 (€ 19,449) Unfavourable step	▲ € 288,959
Balance sheet total	€ 46,094 Balance sheet total 2022: € 46,094 First fiscal year in the series	€ 166,368 Balance sheet total 2023: € 166,368 ▲ 261% vs 2022 (€ 46,094) Unchanged	€ 243,800 Balance sheet total 2024: € 243,800 ▲ 47% vs 2023 (€ 166,368) Unchanged	€ 465,831 Balance sheet total 2025: € 465,831 ▲ 91% vs 2024 (€ 243,800) Unchanged	▲ 91%

Key figures of MEDOXY, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MEDOXY?

What happened at MEDOXY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 26, 2026 New annual accounts for financial year 2025: profit of € 12,462 (▼ 79% vs 2024). filed late Source: NBB ↗
Sep 2, 2022 New establishment in Neupré. KBO
Sep 2, 2022 Start of the company according to the CBE. KBO

In short

From € 31,245 profit in 2022 to € 12,462 profit in 2025.

Paid € 51,162 in corporate taxes since 2022.

Best year ever: 2023, with € 102,958 profit.

Paid out € 100,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Establishments

Establishment units

Physical locations of this company

Registered office

Rue des Bouvreuils(N) 10

4121 Neupré

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0790.403.510
VAT number: BE 0790.403.510
Registered office: Rue des Bouvreuils(N) 10, 4121 Neupré
Names & denominations: MEDOXY
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 2 September 2022
Peppol: Active · Active since 28 Sept 2025

View on CBE Public ↗ Annual accounts (NBB) ↗

MEDOXY

Financials

What happened to MEDOXY?

Establishments

Establishment units

Details

Frequently asked questions